ArticleValue in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research2011

Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis.

Daniel J Crespin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.